Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma BioPharma DiveInitial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial ResultsNext: Spyre drug for inflammatory bowel disease shows promise in early study Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
